Co-Founder/CEO
Quotient Therapeutics
Quotient Therapeutics utilizes a Somatic Genomics platform to unlock the therapeutic potential of the vast genetic diversity within human cells, enabling the discovery of novel drug candidates. This approach addresses the limitations of traditional genomics by providing insights that lead to targeted treatments for a range of diseases.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$50MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Jacob Rubens
CEO
Product
Problem
Traditional drug discovery methods often overlook the vast genetic diversity within individual human cells, limiting the identification of novel therapeutic targets and drug candidates. This narrow focus fails to capture the full spectrum of potential treatments encoded within the somatic genome.
Solution
Quotient Therapeutics leverages a Somatic Genomics platform to unlock the therapeutic potential of the genetic diversity found within human cells. This platform enables the discovery of novel drug candidates by providing insights into previously unexplored genetic variations. By analyzing the somatic genome, Quotient Therapeutics aims to develop targeted treatments for a range of diseases, overcoming the limitations of traditional genomic approaches. The platform facilitates the identification of unique therapeutic targets and the development of more effective and personalized medicines.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking novel drug targets and innovative approaches to drug discovery.
Features
- Somatic Genomics platform for analyzing genetic variations within individual cells
- Identification of novel therapeutic targets based on somatic mutations
- Development of targeted treatments for a range of diseases
- Insights into previously unexplored genetic variations